INCREASED LEVELS OF BETA-HUMAN ATRIAL NATRIURETIC PEPTIDE-LIKE IMMUNOREACTIVITY IN CHRONICALLY OVERLOADED ATRIAL TISSUE

被引：9

作者：

NARUSE, M

HIROE, M

NARUSE, K

NAGATA, M

OHNO, H

HASHIMOTO, A

KOYANAGI, H

SEKIGUCHI, M

DEMURA, H

HIROSAWA, K

INAGAMI, T

SHIZUME, K

机构：

[1] The Department of Medicine, Institute of Clinical Endocrinology

[2] Department of Radiology, Tokyo Women‘s Medical College, Tokyo

[3] Central Research Laboratory, Mitsubishi Petrochemical Company Ltd, Ibaragi

[4] Department of Surgery, The Heart Institute of Japan, Tokyo Women‘s Medical College, Tokyo

[5] Department of Biochemistry, Vanderbilt University, Nashville, TN

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1990年 / 3卷 / 02期

关键词：

Atrial fibrillation; Atrial natriuretic peptide; Atrial pressure; Mitral disease;

D O I：

10.1093/ajh/3.2.105

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The levels and molecular form of atrial natriuretic peptide-like immunoreactivity (ANP-LI) in human atrial tissue were investigated. The levels of right atrial ANP-LI were significantly higher in mitral disease than in other cardiac or noncardiac diseases. The increased ANP-LI was mainly accounted for by an increase in β-human ANP-LI (β-hANP-LI). Both total ANP-LI and β-hANP-LI levels were associated with the presence of atrial fibrillation and with increased atrial pressure. Plasma β-hANP-LI levels were also increased in mitral disease. These results suggest that human atrium with hemodynamic overloads is characterized by increased tissue levels of ANP and by a shift to the β-hANP form. © 1990 by the American Journal of Hypertension, Ltd.

引用

页码：105 / 110

页数：6

共 17 条

[1]

Cantin M., Genest J., The heart and the atrial natriuretic factor, Endocrine Rev, 6, pp. 107-127, (1985)

[2]

Laragh J.H., Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis, New Engl J Med, 313, pp. 1330-1340, (1985)

[3]

Burnett J.C., Granger J.P., Opgenorth T.J., Effects of synthetic atrial natriuretic factor on renal function and renin release, Am J Physiol, 247, pp. F863-F866, (1984)

[4]

Maack T., Marion D.N., Camargo M.J.F., Et al., Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs, Am J Med, 77, pp. 1069-1075, (1984)

[5]

Samson W.K., Atrial natriuretic factor inhibits dehydration and hemorrhage-induced vasopressin release, Neuroendocrinology, 40, pp. 277-279, (1985)

[6]

Kangawa K., Matsuo H., Purification and complete amino acid sequence of human atrial natriuretic polypeptide (α-hANP), Biochem Biophys Res Commun, 118, pp. 131-139, (1984)

[7]

Kangawa K., Fukuda A., Matsuo H., Structural identification of beta- and gamma-human atrial natriuretic polypeptides (α- and γ-hANP), Nature, 313, pp. 397-400, (1985)

[8]

Sugawara A., Nakao K., Morii N., Et al., Augmented synthesis of β-human atrial natriuretic polypeptide in human failing hearts, Biochem Biophys Res Commun, 150, pp. 60-67, (1988)

[9]

Naruse M., Naruse K., Obana K., Et al., Immunoreactive α-human atrial natriuretic polypeptide in human plasma, Peptides, 7, pp. 141-147, (1986)

[10]

Dietz J.R., Release of natriuretic factor from rat heart-lung preparation by atrial distension, Am J Physiol, 247, pp. R1093-R1096, (1984)

← 1 2 →